{"id":"W2553702823","doi":"10.1182/blood.v124.21.5734.5734","title":"A Phase II Study of AT9283, an Aurora Kinase Inhibitor, in Patients with Relapased or Refractory Multiple Myloma; NCIC Clinical Trials Group IND.191","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary; Princess Margaret Cancer Centre; University of Alberta; Juravinski Cancer Centre; Saint John Regional Hospital; Dalhousie University; University of New Brunswick; Queen's University","funders":"","keywords":"Medicine; Multiple myeloma; Aurora inhibitor; Internal medicine; Clinical endpoint; Refractory (planetary science); Oncology; Phases of clinical research; Aurora kinase; Clinical trial; Aurora B kinase; Gastroenterology; Pharmacology; Cancer; Cell cycle; Cytokinesis; Chemistry; Cell; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001848762,0.001579414,0.002363176,0.0005700456,0.0005252693,0.0008468283,0.001175836,0.001659417,0.004767807],"category_scores_gemma":[0.0008777688,0.0005981749,0.001009627,0.000617856,0.0008642927,0.0006203717,0.000369244,0.003665906,0.001167684],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006986064,"about_ca_system_score_gemma":0.001541387,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001219221,"about_ca_topic_score_gemma":0.001973713,"domain_scores_codex":[0.9995341,0.0002304573,0.00002279126,0.00007897287,0.00004678711,0.00008690514],"domain_scores_gemma":[0.9993228,0.0001263632,0.0001034754,0.00005694186,0.00005341108,0.0003370309],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7412212,0.07152636,0.005775854,0.001593581,0.001240696,0.0006220025,0.0003556419,0.00357348,0.05129862,0.0005190682,0.01045537,0.1118181],"study_design_scores_gemma":[0.731814,0.255492,0.006598188,0.00004022971,0.0002791034,0.0002646929,0.00002859125,0.001209128,0.001923039,0.0001623084,0.002163425,0.00002539907],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9813896,0.003827998,0.0008821494,0.0009027568,0.0001653581,0.006966909,0.0020444,0.0002518068,0.003569141],"genre_scores_gemma":[0.9778135,0.002281618,0.002819695,0.00148555,0.000239182,0.008205688,0.002932808,0.0000531712,0.004168778],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004767807,"threshold_uncertainty_score":0.0159499,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03187653087238147,"score_gpt":0.3314587685954111,"score_spread":0.2995822377230297,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}